Image Place holder

Jing-Yi Chern, MD, ScM

Specialty: Gynecologic Oncology
Program: Gynecologic Oncology

Call 1-888-MOFFITT

Call 1-888-MOFFITT

Locations: Moffitt Cancer Center

Cancer Types Treated: Ovarian Cancer , Vaginal Cancer , Vulvar Cancer, Cervical Cancer, Endometrial (Uterine) Cancer

Dr. Chern is a Gynecologic Oncologist.  After earning her Master’s Degree in Biochemistry and Molecular Biology at the Johns Hopkins University Bloomberg School of Public Health in Baltimore, Dr. Chern completed her Medical Degree at the University of South Florida College of Medicine. She subsequently completed her Residency in Obstetrics and Gynecology at the University of South Florida, where she served as Administrative Chief Resident and Scientific Review Committee Member. Dr. Chern completed her Gynecologic Oncology Fellowship at New York University School of Medicine, where she earned a Certificate in Translational Research Methodologies under the Clinical and Translational Science Institute. Her clinical focus is to provide personalized and comprehensive care for women with gynecologic cancers, with a special interest in the surgical management of advanced malignancies. Dr. Chern also emphasizes the utilization of minimally invasive surgery, including the Robotic platform. Dr. Chern’s research interest includes evaluating quality and safety measures to improve surgical outcomes in patients with malignancies. Dr. Chern has worked as part of a multi-disciplinary team to develop new protocols and safety measures with the goal of improving post-operative outcomes and patient satisfaction. In addition, her research is involved in understanding genetic factors associated with gynecologic malignancies to improve and guide patient care.  

Education & Training


  • New York University School of Medicine - Gynecologic Oncology
  • Memorial Sloan Kettering - Galloway Fellowship


  • University of South Florida - Obstetrics & Gynecology

Medical School:

  • University of South Florida - MD
Participating Trials

Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer: Prospective Study of Pharmacokinetics Patterns and Underlying Biology.
Condition: Gynecological Tumor
Intervention: Paraplatin (carboplatin); Taxol (paclitaxel); carboplatin; paclitaxel

STARTRK-2: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Condition: Thoracic
Intervention: Entrectinib

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Yervoy (Ipilimumab)

A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab in BRCA1 and BRCA2 Mutation Carriers with Recurrent Ovarian Cancer
Condition: Gynecological Tumor
Intervention: CP-675,206 (tremelimumab); Olaparib (Lynparza); tremelimumab

Phase II study of stereotactic body radiation therapy and atezolizumab in the management of recurrent, persistent, or metastatic cervical cancer
Condition: Gynecological Tumor
Intervention: Atezolizumab (Tecentriq)

A Phase III Randomised, Double-Blind, Placebo-Controlled,Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).
Condition: Gynecological Tumor
Intervention: AMP-514 (Durvalumab); Avastin (Bevacizumab); Bevacizumab; Durvalumab; MEDI4736 (Durvalumab); Olaparib (Lynparza); Paraplatin (carboplatin); Placebo; Taxol (paclitaxel); carboplatin; paclitaxel

A Randomized, Double-Blind, Phase 3 Trial Of Maintenance With Selinexor/Placebo After Combination Chemotherapy For Patients With Advanced Or Recurrent Endometrial Cancer
Condition: Gynecological Tumor
Intervention: KPT-330 (Selinexor); Placebo; Selinexor

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826)
Condition: Gynecological Tumor
Intervention: Avastin (Bevacizumab); Bevacizumab; Paraplatin (carboplatin); Pembrolizumab (Keytruda); Placebo; Taxol (paclitaxel); carboplatin; cisplatin; paclitaxel

Feasibility Study for Electroacupuncture for Chemotherapy- Induced Peripheral Neuropathy (CIPN) Using a Point-Of-Nerve Conduction Device (NeuroMetrix) and the Rydel-Seiffer Tuning Fork
Condition: Gynecological Tumor
Intervention: Not Applicable

A Phase 2 Open-Label, Single-Arm Study To Evaluate the Efficacy and Safety of the Combination OF Niraparib and TSR-042 in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Condition: Gynecological Tumor
Intervention: Niraparib; TSR-042

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.


  • Chern JY, Lee SS, Frey MK, Lee J, Blank SV. The influence of BRCA variants of unknown significance on cancer risk management decision-making. J Gynecol Oncol. 2019 Jul;30(4):e60. Pubmedid: 31074248. Pmcid: PMC6543104.
  • Madden N, Frey MK, Joo L, Lee J, Musselman K, Chern JY, Blank SV, Pothuri B. Safety of robotic-assisted gynecologic surgery and early hospital discharge in elderly patients. Am J Obstet Gynecol. 2018 Dec. Pubmedid: 30557552.
  • Chern JY, Boyd LR, Blank SV. Uterine Sarcomas: The Latest Approaches for These Rare but Potentially Deadly Tumors. Oncology (Williston Park). 2017 Mar;31(3):229-236. Pubmedid: 28299760.
  • Frey MK, Ellis AE, Koontz LM, Shyne S, Klingenberg B, Fields JC, Chern JY, Blank SV. Ovarian cancer survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum. Gynecol Oncol. 2017 Aug;146(2):386-391. Pubmedid: 28602549.
  • Lee J, Aphinyanaphongs Y, Curtin JP, Chern JY, Frey MK, Boyd LR. The safety of same-day discharge after laparoscopic hysterectomy for endometrial cancer. Gynecol Oncol. 2016 Sep;142(3):508-513. Pubmedid: 27288543.
  • Frey MK, Moss HA, Musa F, Rolnitzky L, David-West G, Chern JY, Boyd LR, Curtin JP. Preoperative experience for public hospital patients with gynecologic cancer: Do structural barriers widen the gap?. Cancer. 2016 Mar;122(6):859-867. Pubmedid: 26938270.
  • Chern JY, Curtin JP. Appropriate Recommendations for Surgical Debulking in Stage IV Ovarian Cancer. CURR TREAT OPTION ON. 2016 Jan;17(1):1. Pubmedid: 26714493.
  • Frey MK, Kim SH, Bassett RY, Martineau J, Dalton E, Chern JY, Blank SV. Rescreening for genetic mutations using multi-gene panel testing in patients who previously underwent non-informative genetic screening. Gynecol Oncol. 2015 Nov;139(2):211-215. Pubmedid: 26296696.
  • McLoughlin J, Melis M, Siegel E, Dean E, Weber J, Chern J, Elliott M, Kelley S, Karl R. Are patients with esophageal cancer who become PET negative after neoadjuvant chemoradiation free of cancer?. J Am Coll Surg. 2008 May;206(5):879-886. Pubmedid: 18471715.
  • Hohenstein KA, Pyle AD, Chern JY, Lock LF, Donovan PJ. Nucleofection mediates high-efficiency stable gene knockdown and transgene expression in human embryonic stem cells. Stem Cells. 2008 Jun;26(6):1436-1443. Pubmedid: 18323409. Pmcid: PMC3882114.
  • Charron M, Chern JY, Wright WW. The cathepsin L first intron stimulates gene expression in rat sertoli cells. Biol Reprod. 2007 May;76(5):813-824. Pubmedid: 17229931.